Vše

Co hledáte?

Vše
Projekty
Výsledky výzkumu
Subjekty

Rychlé hledání

  • Projekty podpořené TA ČR
  • Významné projekty
  • Projekty s nejvyšší státní podporou
  • Aktuálně běžící projekty

Chytré vyhledávání

  • Takto najdu konkrétní +slovo
  • Takto z výsledků -slovo zcela vynechám
  • “Takto můžu najít celou frázi”

Apoferritin as an ubiquitous nanocarrier with excellent shelf life

Identifikátory výsledku

  • Kód výsledku v IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62156489%3A43210%2F17%3A43911471" target="_blank" >RIV/62156489:43210/17:43911471 - isvavai.cz</a>

  • Nalezeny alternativní kódy

    RIV/00216305:26620/17:PU123312

  • Výsledek na webu

    <a href="https://doi.org/10.2147/IJN.S130267" target="_blank" >https://doi.org/10.2147/IJN.S130267</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.2147/IJN.S130267" target="_blank" >10.2147/IJN.S130267</a>

Alternativní jazyky

  • Jazyk výsledku

    angličtina

  • Název v původním jazyce

    Apoferritin as an ubiquitous nanocarrier with excellent shelf life

  • Popis výsledku v původním jazyce

    Due to many adverse effects of conventional chemotherapy, novel methods of targeting drugs to cancer cells are being investigated. Nanosize carriers are a suitable platform for this specific delivery. Herein, we evaluated the long-term stability of the naturally found protein nanocarrier apoferritin (Apo) with encapsulated doxorubicin (Dox). The encapsulation was performed using Apo&apos;s ability to disassemble reversibly into its subunits at low pH (2.7) and reassemble in neutral pH (7.2), physically entrapping drug molecules in its cavity (creating ApoDox). In this study, ApoDox was prepared in water and phosphate-buffered saline and stored for 12 weeks in various conditions (-20oC, 4oC, 20oC, and 37oC in dark, and 4oC and 20oC under ambient light). During storage, a very low amount of prematurely released drug molecules were detected (maximum of 7.5% for ApoDox prepared in PBS and 4.4% for ApoDox prepared in water). Fourier-transform infrared spectra revealed no significant differences in any of the samples after storage. Most of the ApoDox prepared in phosphate-buffered saline and ApoDox prepared in water and stored at -20oC formed very large aggregates (up to 487% of original size). Only ApoDox prepared in water and stored at 4oC showed no significant increase in size or shape. Although this storage caused slower internalization to LNCaP prostate cancer cells, ApoDox (2.5 µM of Dox) still retained its ability to inhibit completely the growth of 1.5x104 LNCaP cells after 72 hours. ApoDox stored at 20oC and 37oC in water was not able to deliver Dox inside the nucleus, and thus did not inhibit the growth of the LNCaP cells. Overall, our study demonstrates that ApoDox has very good stability over the course of 12 weeks when stored properly (at 4oC), and is thus suitable for use as a nanocarrier in the specific delivery of anticancer drugs to patients.

  • Název v anglickém jazyce

    Apoferritin as an ubiquitous nanocarrier with excellent shelf life

  • Popis výsledku anglicky

    Due to many adverse effects of conventional chemotherapy, novel methods of targeting drugs to cancer cells are being investigated. Nanosize carriers are a suitable platform for this specific delivery. Herein, we evaluated the long-term stability of the naturally found protein nanocarrier apoferritin (Apo) with encapsulated doxorubicin (Dox). The encapsulation was performed using Apo&apos;s ability to disassemble reversibly into its subunits at low pH (2.7) and reassemble in neutral pH (7.2), physically entrapping drug molecules in its cavity (creating ApoDox). In this study, ApoDox was prepared in water and phosphate-buffered saline and stored for 12 weeks in various conditions (-20oC, 4oC, 20oC, and 37oC in dark, and 4oC and 20oC under ambient light). During storage, a very low amount of prematurely released drug molecules were detected (maximum of 7.5% for ApoDox prepared in PBS and 4.4% for ApoDox prepared in water). Fourier-transform infrared spectra revealed no significant differences in any of the samples after storage. Most of the ApoDox prepared in phosphate-buffered saline and ApoDox prepared in water and stored at -20oC formed very large aggregates (up to 487% of original size). Only ApoDox prepared in water and stored at 4oC showed no significant increase in size or shape. Although this storage caused slower internalization to LNCaP prostate cancer cells, ApoDox (2.5 µM of Dox) still retained its ability to inhibit completely the growth of 1.5x104 LNCaP cells after 72 hours. ApoDox stored at 20oC and 37oC in water was not able to deliver Dox inside the nucleus, and thus did not inhibit the growth of the LNCaP cells. Overall, our study demonstrates that ApoDox has very good stability over the course of 12 weeks when stored properly (at 4oC), and is thus suitable for use as a nanocarrier in the specific delivery of anticancer drugs to patients.

Klasifikace

  • Druh

    J<sub>imp</sub> - Článek v periodiku v databázi Web of Science

  • CEP obor

  • OECD FORD obor

    10406 - Analytical chemistry

Návaznosti výsledku

  • Projekt

    Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

  • Návaznosti

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Ostatní

  • Rok uplatnění

    2017

  • Kód důvěrnosti údajů

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Údaje specifické pro druh výsledku

  • Název periodika

    International Journal of Nanomedicine

  • ISSN

    1176-9114

  • e-ISSN

  • Svazek periodika

    12

  • Číslo periodika v rámci svazku

    24 March

  • Stát vydavatele periodika

    NZ - Nový Zéland

  • Počet stran výsledku

    14

  • Strana od-do

    2265-2278

  • Kód UT WoS článku

    000397274500001

  • EID výsledku v databázi Scopus

    2-s2.0-85016330513